“CD28 blockade” has been long referred to as use of CTLA4-Ig. However it has now been recognized that CTLA4-Ig, which actually binds CD80/86, inhibits CD28-mediated costimulation as well as CTLA-4 and PDL-1 co-inhibitory signals that are important immune checkpoint inhibitors also involved in the control of Treg suppression. The development of non-agonist monovalent anti-CD28 antibodies made it possible to study the biological and therapeutic impacts of “selective CD28 blockade”. First, selective CD28 antagonists are able to differentially control effector and regulatory T cells. Second, they are very effective at blocking memory T cell responses, which in primates are under the dependency of CD28 and CTLA-4/PD-1. In vivo, selective CD28 antagonists have demonstrated efficacy in preclinical primate models of heart, kidney and bone marrow transplantation, as well as in autoimmune encephalomyelitis, skin inflammation and collagen arthritis models. A major finding drawn from these experiments is the possibility to induce an antigen-specific hyporesponsiveness, the mechanisms of which stays to be further defined. Selective CD28 antagonists have initiated their clinical development and might become a new therapeutic paradigm in autoimmunity and transplantation.
Disclosure of Interest B. Vanhove Shareholder of: Shareholder of Effimune
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.